myeloid

Documents about myeloid

• Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML#900843ClinicalTrials.gov
• Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia#852418ClinicalTrials.gov
• Acute Myeloid Leukemia Real World Treatment Patterns#898909ClinicalTrials.gov
• Biomarkers in Patients With Acute Myeloid Leukemia#857792ClinicalTrials.gov
• Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia#825840ClinicalTrials.gov
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia#835816ClinicalTrials.gov
• CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia#417542ClinicalTrials.gov
• Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia#911774ClinicalTrials.gov
• Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)#825220ClinicalTrials.gov
• Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia#834181ClinicalTrials.gov
• Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents#873259ClinicalTrials.gov
• Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma#230398ClinicalTrials.gov
• A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia#910762ClinicalTrials.gov
• Targeting residual malignant cells in myeloid leukemia#642966GUPEA
• Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia#884716ClinicalTrials.gov
• Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia#804292ClinicalTrials.gov
• Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia#906220ClinicalTrials.gov
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia#835326ClinicalTrials.gov
• MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia#826459ClinicalTrials.gov
• Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients#906041ClinicalTrials.gov
• SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation#852632ClinicalTrials.gov
• Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia#886251ClinicalTrials.gov
• A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia#895578ClinicalTrials.gov
• Frequency and Risk Factors of Acute Myeloid Leukemia#866279ClinicalTrials.gov
• Chronic Myeloid Leukemia (CML) Real-Life Database#893218ClinicalTrials.gov
• Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia#861849ClinicalTrials.gov
• Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission#407778ClinicalTrials.gov
• Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers#887342ClinicalTrials.gov
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm#349954ClinicalTrials.gov
• Mismatched Donor Cells to Treat Acute Myeloid Leukemia#226264ClinicalTrials.gov
• Beat AML Core Study#802158ClinicalTrials.gov
• Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia#874677ClinicalTrials.gov
• Chronic Myelod Leukemia Registry at Asan Medical Center#882364ClinicalTrials.gov
• 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia#883980ClinicalTrials.gov
• A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia#826900ClinicalTrials.gov
• CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old#831859ClinicalTrials.gov
• Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia#898835ClinicalTrials.gov
• Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation#886459ClinicalTrials.gov
• Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia#832732ClinicalTrials.gov
• Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia#856096ClinicalTrials.gov
• Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors#860477ClinicalTrials.gov
• The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma#861235ClinicalTrials.gov
• Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia#863606ClinicalTrials.gov
• MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia#878283ClinicalTrials.gov
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia#899354ClinicalTrials.gov
• Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia#290983ClinicalTrials.gov
• CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)#668834ClinicalTrials.gov
• Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients#890827ClinicalTrials.gov
• Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531#803865ClinicalTrials.gov
• Master Framework For Relapse or Refractory Acute Myeloid Leukemia#908953ClinicalTrials.gov